Avenue Therapeutics enrolls 8th patient in SBMA trial, triggering 276,652 share issuance to AnnJi

AVENUE THERAPEUTICS, INC.

Enrolled eighth patient in Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy (SBMA).
Issued 276,652 shares of common stock to AnnJi as Second Tranche Shares under license agreement.
Trial is 12-week, multicenter, randomized, double-blind, targeting ~24 patients; primary endpoint safety/tolerability.
AJ201 activates Nrf1/Nrf2 and enhances androgen receptor degradation; previously paid $3M cash and 831,618 shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.